Authorized Generic

Quote






anonymous said:
Mix some vodka with your Kool-Aid, and take a look at the national Rx data. More than an Rx or 2! And it’s only 6 weeks in.
Click to expand...

and look at the Jardiance Rx data you idiot. Also growing.

stay on strategy. Don’t worry about AG unless doctor brings it up. Any health plans or PBMs that have Rx’s going through will start to do more to drop it. It makes ZERO business sense for a plan to have the AG covered in any way. Think about the finances.
 






anonymous said:
and look at the Jardiance Rx data you idiot. Also growing.

stay on strategy. Don’t worry about AG unless doctor brings it up. Any health plans or PBMs that have Rx’s going through will start to do more to drop it. It makes ZERO business sense for a plan to have the AG covered in any way. Think about the finances.
Click to expand...
Stay on strategy! Yes sir, captain ass clown!
Let’s talk again in 6 months.
 






anonymous said:
and look at the Jardiance Rx data you idiot. Also growing.

stay on strategy. Don’t worry about AG unless doctor brings it up. Any health plans or PBMs that have Rx’s going through will start to do more to drop it. It makes ZERO business sense for a plan to have the AG covered in any way. Think about the finances.
Click to expand...
Perfect example of a manager who thinks he knows what the PBMs and plans are going to do and what the contracts look like. Doctors want to prescribe generics, they don’t care about your sales pitch BS “strategy”.
 






anonymous said:
and look at the Jardiance Rx data you idiot. Also growing.

stay on strategy. Don’t worry about AG unless doctor brings it up. Any health plans or PBMs that have Rx’s going through will start to do more to drop it. It makes ZERO business sense for a plan to have the AG covered in any way. Think about the finances.
Click to expand...
Can you explain where these Rx are coming from and what the financial benefits/downside is to each plan, patient and HCP who writes the Rx? Why were they written? Maybe if you spelled it out we would believe you. In our region no one has been able to explain it and the leaders look just as shocked as the reps. The “strategy” is to change the subject. Most HCPs are pretty smart and already have distrust for industry so this “strategy” doesn’t impress anyone except the kool-aid drinkers.
 






anonymous said:
if (big IF) they are able to move any of their branded volume to the AG, it should help reduce their rebate exposure. The AG discount is much lower than any commercial, Medicare or Medicaid rebates they’re paying.
Click to expand...
How do you know this on a national level? Health systems and plans do not make contracts public. You do not know what each plan/hospital is paying for the AG. WAC prices get negotiated all of the time. And every state is different.
 






Bottom line is, generic has exclusivity for six months that’s why they charge a higher price but not as high as branded. Then other companies produce and the price drops. September is when the hatchet will fall. Very lucky if we make it to December. Syneos contract ends in December. All good things come to an end.
 












Ok, here are some facts.

-this is not a true generic. It is an authorized generic. Manufactured by AZ. It is NOT multi source and branded Farxiga is still under patent protection. There is no ‘6 month of exclusivity’ with this product bc it is essentially a branded agent. ‘Real’ generic Dapa will not be available until end of ‘25 (unless AZ gets an additional extension with a pediatric indication). Regardless, there won’t be a multi source generic Dapa until early in ‘26.

-Prasco/AZ is selling it at a 35% discount off WAC price. Branded Farxiga is closer to a 70%+ rebate with commercial and Medicare plans and PBM’s. Do the math. Which would a health plan prefer? 35% discount or a 70% rebate? Branded Fx is also close to 100% for Medicaid.

-Any plan or PBM that puts the generic on will put their JD (and FX) rebates at risk. That is a multi million dollar risk that they will NOT want to deal with.

-Any Rx’s for the AG are likely through plans that have an open formulary that automatically put new products on. Plans have up to 6 months to review the AG. It is highly likely that plans that DO have the AG ‘covered’ will restrict its use in the next 3 months.

please stop all the other nonsense fear mongering. Reps posting on here have NO clue what they are referring to. Jardiance continues to perform well. There have been no formulary coverage losses. Stay on strategy. AZ has a bunch of mook contract reps promoting a product and the AG. All they are doing is confusing doctors and trying to raise perception that the AG is a generic (see above…it’s not). Docs are confused. There’s no confusion with Jardiance.
 






anonymous said:
Bottom line is, generic has exclusivity for six months that’s why they charge a higher price but not as high as branded. Then other companies produce and the price drops. September is when the hatchet will fall. Very lucky if we make it to December. Syneos contract ends in December. All good things come to an end.
Click to expand...

you’re wrong. This is not an actual generic and AZ still has close to 2 years of patent protection. Previous poster is correct. Farxiga won’t have a multi sourced generic until 6 months after its LOE which is late ‘25z
 






anonymous said:
Perfect example of a manager who thinks he knows what the PBMs and plans are going to do and what the contracts look like. Doctors want to prescribe generics, they don’t care about your sales pitch BS “strategy”.
Click to expand...

manager or not, the poster above is correct with their facts.

you make a lot of assumptions and how do you know the poster is a manager?
 






anonymous said:
Stay on strategy! Yes sir, captain ass clown!
Let’s talk again in 6 months.
Click to expand...

in 6 months, the AG will be a non issue. Plans will continue to remove or block it from formulary.

plans make decisions based on finances. There is NO reason for them to add the AG. Even with discounts, it is more expensive than FX and JD when you factor in rebates. Significantly more expensive.
 






anonymous said:
in 6 months, the AG will be a non issue. Plans will continue to remove or block it from formulary.

plans make decisions based on finances. There is NO reason for them to add the AG. Even with discounts, it is more expensive than FX and JD when you factor in rebates. Significantly more expensive.
Click to expand...

The main issue that no one knows is if AZ will continue to pay rebates and keep their coverage for 2025 or will they go all out with getting their AG on every formulary. It has been asked on many calls with no one having a clue which way they will go. We should know by October/ November what next year’s formularies look like.
 






anonymous said:
in 6 months, the AG will be a non issue. Plans will continue to remove or block it from formulary.

plans make decisions based on finances. There is NO reason for them to add the AG. Even with discounts, it is more expensive than FX and JD when you factor in rebates. Significantly more expensive.
Click to expand...

It sounds like you do know what you are talking about, but it is not that black and white. JD will lose business as long as the AG is covered, and then when (if) plans start to block it, most of those AG Rx’s will switch to FX. And you did not mention hospitals adding the AG as exclusive. HCPs will continue to TRY and write it wherever they can, because they want a generic for their patient and for their generic performance measures. When it gets blocked at the pharmacy, most of it will get converted to a FX Rx. The sky is not falling, but we need to be realistic. AZ is not new to this. we will lose share and net sales. Things change, and this is one of them. Life goes on!
 






anonymous said:
It sounds like you do know what you are talking about, but it is not that black and white. JD will lose business as long as the AG is covered, and then when (if) plans start to block it, most of those AG Rx’s will switch to FX. And you did not mention hospitals adding the AG as exclusive. HCPs will continue to TRY and write it wherever they can, because they want a generic for their patient and for their generic performance measures. When it gets blocked at the pharmacy, most of it will get converted to a FX Rx. The sky is not falling, but we need to be realistic. AZ is not new to this. we will lose share and net sales. Things change, and this is one of them. Life goes on!
Click to expand...
Not going to lose net sales. These scripts are the bottom dwellers.
 






anonymous said:
Not going to lose net sales. These scripts are the bottom dwellers.
Click to expand...
The bigger issue and strategy from AZ is to inform the HCP's that there is a generic for farxiga and misleadingly know that it will not be covered and knowing then that the pharmacy will automatically give them the brand name that will be covered. Kind of a "bait and switch tactic". And remember all HCP's that see both old and young patients love to hear the word "generic".
 






anonymous said:
It sounds like you do know what you are talking about, but it is not that black and white. JD will lose business as long as the AG is covered, and then when (if) plans start to block it, most of those AG Rx’s will switch to FX. And you did not mention hospitals adding the AG as exclusive. HCPs will continue to TRY and write it wherever they can, because they want a generic for their patient and for their generic performance measures. When it gets blocked at the pharmacy, most of it will get converted to a FX Rx. The sky is not falling, but we need to be realistic. AZ is not new to this. we will lose share and net sales. Things change, and this is one of them. Life goes on!
Click to expand...
 






anonymous said:
Ok, here are some facts.

-this is not a true generic. It is an authorized generic. Manufactured by AZ. It is NOT multi source and branded Farxiga is still under patent protection. There is no ‘6 month of exclusivity’ with this product bc it is essentially a branded agent. ‘Real’ generic Dapa will not be available until end of ‘25 (unless AZ gets an additional extension with a pediatric indication). Regardless, there won’t be a multi source generic Dapa until early in ‘26.

-Prasco/AZ is selling it at a 35% discount off WAC price. Branded Farxiga is closer to a 70%+ rebate with commercial and Medicare plans and PBM’s. Do the math. Which would a health plan prefer? 35% discount or a 70% rebate? Branded Fx is also close to 100% for Medicaid.

-Any plan or PBM that puts the generic on will put their JD (and FX) rebates at risk. That is a multi million dollar risk that they will NOT want to deal with.

-Any Rx’s for the AG are likely through plans that have an open formulary that automatically put new products on. Plans have up to 6 months to review the AG. It is highly likely that plans that DO have the AG ‘covered’ will restrict its use in the next 3 months.

please stop all the other nonsense fear mongering. Reps posting on here have NO clue what they are referring to. Jardiance continues to perform well. There have been no formulary coverage losses. Stay on strategy. AZ has a bunch of mook contract reps promoting a product and the AG. All they are doing is confusing doctors and trying to raise perception that the AG is a generic (see above…it’s not). Docs are confused. There’s no confusion with Jardiance.
Click to expand...
 












anonymous said:
Sorry, doc said today the pharmacy called and said they will decide whether farxiga or generic. They don’t care about plans, rebates, etc
Click to expand...

wrong. Pharmacy has NO influence over what is prescribed. It all depends on the doctor and the patient’s insurance/pharmacy benefit.

pharmacists have 1 job, Dispense. Nothing else.
 






Top Bottom
Back
Quote